FRANKLIN, NEW JERSEY / ACCESS Newswire / October 2, 2025 / Silver Scott today announced the upcoming release of its proprietary AI engine designed to transform patient intake and triage for AffordableTelehealthPlan.com, the company's new healthcare platform aimed at providing affordable, accessible care for millions of underserved Americans. The AI engine enables patients to describe their symptoms by text, voice, or video. ...

Core Viewpoint - A federal securities fraud class action lawsuit has been filed against LifeMD, Inc. and its executives, alleging that the company misrepresented its financial health and growth prospects, leading to a significant decline in stock price in August 2025 [1][6]. Summary by Relevant Sections Lawsuit Details - The lawsuit, titled Johnston v. LifeMD, Inc., seeks to recover damages for investors who purchased LifeMD securities during the class period from May 7, 2025, to August 5, 2025 [2][8]. Financial Misrepresentation - The lawsuit centers on LifeMD's financial guidance and public statements made after reporting strong Q1 results on May 6, 2025, where the company raised its full-year revenue and adjusted EBITDA guidance, claiming a "category-defining competitive moat" in virtual obesity care and strong performance from its RexMD brand [6][7]. - The complaint alleges that this positive outlook was misleading as the company failed to disclose ongoing business challenges affecting revenue streams, including elevated customer acquisition costs and high patient refund rates [7][9]. Stock Price Impact - The issues came to light on August 5, 2025, when LifeMD announced its second-quarter results, missing revenue and earnings per share estimates, and subsequently slashed its full-year guidance. Following this announcement, LifeMD's stock price dropped by over 44% [7][9]. Investigation and Legal Action - Hagens Berman, a plaintiffs' rights firm, is investigating these claims on behalf of investors who suffered losses during the class period, focusing on when management became aware of the adverse information and whether their failure to disclose misled investors [10][11].

"It wasn't just a blip." Tennis star Serena Williams delivers a surge in demand for the telehealth site Ro, after opening up about her 30-pound weight-loss experience in an ad for its services. https://t.co/V45OcbyJfO ...

Core Insights - Hims & Hers stock (NASDAQ: HIMS) has surged 42% over the past month, rising from approximately $42 to $59, primarily due to the dismissal of a lawsuit by Eli Lilly against rival telehealth company Willow Health, alleviating investor concerns regarding legal risks for Hims [2][4]. Company Overview - Hims & Hers Health operates a telehealth platform that connects consumers to licensed professionals, offering non-prescription wellness supplements and medical consultations through direct and wholesale channels, with a current market cap of $13 billion [6]. Financial Performance - Hims & Hers has experienced significant revenue growth, with a 76.3% average growth rate over the past three years and an 89% increase in revenues from $1.1 billion to $2.0 billion in the last 12 months [9]. - Quarterly revenues rose by 72.6% to $545 million from $316 million year-over-year [9]. - The company reported an operating income of $126 million, resulting in an operating margin of 6.2%, and a net income of nearly $194 million, reflecting a net margin of approximately 9.6% [9]. - Hims & Hers has a cash flow margin of 13.0%, generating nearly $262 million in operating cash flow during the same period [9]. Debt and Financial Stability - The company had $1.0 billion in debt at the end of the most recent quarter, leading to a Debt-to-Equity Ratio of 7.9% [9]. - Cash and cash equivalents amount to $1.1 billion out of total assets of $1.9 billion, resulting in a Cash-to-Assets Ratio of 61.0% [9]. Market Valuation and Performance - Despite strong operational performance, the current valuation of HIMS stock appears high following the recent surge [5]. - Hims & Hers stock has shown resilience during economic downturns, performing slightly better than the S&P 500 index [8].

Core Insights - LifeMD, Inc. has announced a collaboration with Novo Nordisk to provide Ozempic at a reduced price of $499 per month for eligible self-pay patients [1][2] - The integration with NovoCare Pharmacy allows access to all FDA-approved doses of Ozempic through LifeMD's virtual care platform [1][2] - The initiative aims to improve access to GLP-1 therapies for millions of Americans suffering from type 2 diabetes, a condition affecting approximately 36 million people in the U.S. [2][3] Company Overview - LifeMD is a leading provider of virtual primary care, offering telemedicine, laboratory and pharmacy services, and specialized treatment across over 200 conditions [4] - The company utilizes a vertically integrated digital care platform and a 50-state affiliated medical group to enhance access to high-quality and affordable care [4] Collaboration Details - The expanded collaboration with Novo Nordisk includes not only Ozempic but also Wegovy, enhancing LifeMD's ability to deliver competitive self-pay prices for FDA-approved GLP-1 therapies [2][3] - LifeMD's telehealth platform is also integrated with LillyDirect pharmacy to provide access to Zepbound (tirzepatide), further diversifying treatment options for patients [3]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of LifeMD, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose critical information during a specified class period [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from May 7, 2025, to August 5, 2025 [3]. - Allegations include that LifeMD's management overstated the company's competitive position and raised 2025 guidance without properly accounting for increased customer acquisition costs, particularly in the RexMD segment and for obesity treatment drugs like Wegovy and Zepbound [3]. Next Steps for Shareholders - Shareholders who purchased shares during the class period are encouraged to register for the class action by October 25, 2025, to potentially become lead plaintiffs [4]. - Registration will provide shareholders with updates throughout the case lifecycle, and participation incurs no cost or obligation [4]. Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to misleading statements or omissions that inflated LifeMD's stock price [5].

Core Viewpoint - A federal securities fraud class action lawsuit has been filed against LifeMD, Inc. and its executives, alleging that the company misrepresented its financial health and growth, leading to a significant decline in stock price in August 2025 [1][2]. Summary by Relevant Sections Lawsuit Details - The lawsuit, titled Johnston v. LifeMD, Inc., covers the period from May 7, 2025, to August 5, 2025, and seeks to recover damages for investors who incurred substantial losses during this timeframe [2]. Allegations of Misleading Information - The complaint indicates that on May 6, 2025, LifeMD reported strong first-quarter results and raised its full-year revenue and adjusted EBITDA guidance, claiming a "category-defining competitive moat" in virtual obesity care and strong performance from its RexMD brand [4]. - However, the lawsuit argues that this optimistic outlook was misleading as the company allegedly failed to disclose ongoing business challenges, including elevated customer acquisition costs and issues with patient refunds [5][10]. Stock Price Impact - Following the announcement of disappointing second-quarter results on August 5, 2025, which included missed revenue and earnings estimates and a reduction in full-year guidance, LifeMD's stock price fell by over 44% the next day [6][5]. Investigation by Hagens Berman - Hagens Berman, a national plaintiffs' rights firm, is investigating these claims on behalf of affected investors, focusing on whether LifeMD's management accurately represented the company's financial situation [7][8]. Key Issues Identified - The lawsuit highlights two main issues: rising customer acquisition costs in the RexMD segment and a higher-than-anticipated refund rate in the weight management business [10].

Core Insights - Artificial intelligence (AI) is significantly transforming various industries, particularly healthcare, by enhancing efficiency and improving patient outcomes [1][2]. Group 1: AI in Healthcare - The integration of generative and agentic AI is aiding healthcare professionals in making more accurate diagnoses and reducing administrative burdens, which is crucial given the high burnout rates among physicians, with 93% reporting regular burnout [2]. - AI is positioned to address the supply and demand imbalance in healthcare, especially with an aging population, by bridging the gap between efficiency and personalized care [2]. Group 2: Investment Opportunities - Companies utilizing AI to enhance healthcare outcomes are seen as potential investment opportunities, with specific stocks highlighted for their growth potential [3]. - Hims & Hers Health (HIMS) has experienced a 121% increase in stock value in 2025, attributed to its AI-driven telehealth services that streamline administrative tasks [4][5]. - Tempus AI (TEM) is leveraging AI for precision medicine and oncology, with a 128% stock increase in 2025, and is recognized for its contributions to drug discovery for major pharmaceutical companies [8][10][11]. - Boston Scientific (BSX) is using AI to improve medical device performance and has received FDA approval for a new treatment system, contributing to a 17% stock increase in 2025 [12][14].

Core Insights - YieldMax ETFs has launched the YieldMax HIMS Option Income Strategy ETF (NYSE: HIYY), aimed at providing current income through options-based strategies related to Hims & Hers Health Inc (NYSE: HIMS) [1][3] - HIYY does not invest directly in Hims & Hers shares but employs options strategies to generate income streams for shareholders [2] - The fund is categorized as a Group D ETF for distribution purposes, with its initial distribution announcement expected on October 22 [4] Company Insights - Hims & Hers Health Inc is recognized as a prominent player in the consumer health and wellness sector, showing exceptional stock strength [1][6] - The introduction of HIYY allows investors to access income potential linked to a high-growth wellness company without owning the underlying stock [3] Industry Insights - Options-based ETFs like HIYY provide an alternative to traditional dividends, particularly in sectors such as health and wellness where stocks may not frequently pay dividends [6] - YieldMax ETFs are gaining popularity for their customized solutions focused on generating immediate income, appealing to both retail and institutional investors [5]

Core Insights - PrestoDoctor, a subsidiary of Dogecoin Cash, Inc., is expanding its telemedicine services for medical cannabis evaluations to Connecticut, now operating in 19 states across the U.S. [1][4] - Since its launch in 2015, PrestoDoctor has served over 500,000 patients, establishing itself as a trusted platform for medical cannabis telehealth services [2][4]. - The Connecticut launch complies with state regulations that require certifications to be issued by licensed in-state clinicians, facilitating patient access to medical marijuana [3][6]. Company Overview - PrestoDoctor has been operational for 10 years, focusing on providing secure, patient-centered telehealth services [4][5]. - The platform offers flexible payment options, including traditional methods and select cryptocurrencies, reflecting a modern approach to healthcare solutions [4][8]. - The company emphasizes privacy and security in its telehealth workflows, consistent with its operations in other states [8]. Regulatory Compliance - The Connecticut launch aligns with state laws permitting telemedicine for medical marijuana certifications, ensuring that only licensed Connecticut professionals can issue certifications [3][6]. - Patients must complete the registration process with the Connecticut Department of Consumer Protection after receiving a certification [6].